The downgrade to Neutral suggests that Mizuho believes Karuna Therapeutics' stock may not provide significant upside potential relative to the market or its sector in the short term. However, the increase in the price target to $330 implies a positive view on the company's fundamentals or potential growth, which could counterbalance the downgrade's negative impact. The mixed sentiment may lead to a neutral short-term impact on the stock price.